MAP1S

Across TCGA pan-cancer cohorts, MAP1S mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP1S data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAP1S mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP1S expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

HNSC, CCRCC, and UCEC are the cancer types where MAP1S mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.520	0.827	.001	24	view →
CCRCC	OS	Tertile	III,IV	0.849	0.540	.022	17	view →
UCEC	OS	Quartile	II,III,IV	0.487	1.000	.025	8	view →
LSCC	OS	Quartile	II,III,IV	0.695	0.906	.041	5	view →
PDAC	DFS	Tertile	IV	0.217	0.550	.024	4	view →
LUAD	OS	Quartile	II,III,IV	0.676	0.294	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP1S–HNSC (DFS)

Open the HNSC breakdown →